Oncoinvent presents corporate update in live webcast

Oslo, Norway, 29 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, is hosting a live webcast at 8:00 AM CET today, Wednesday, 29 April 2026.

• Presenters: CEO Øystein Soug, CFO Ramzi Amri
• Time: 8:00am CET
• Webcast link: https://qcnl.tv/p/ZTQdC_4834AF6CKrux8XCw  

Highlights:

• Recruited and randomized 37 patients (accumulated, ITT*) into the ovarian Phase 2 trial
• Secured new patent expanding protection for Radspherin^®
• Published positive final data from Phase 1 trial of Radspherin^® to treat ovarian cancer
  • Journal: Gynecologic Oncology
  • Conference: ESGO European Gynaecological Oncology Congress 2026
• Appointed Dr Ramzi Amri as CFO

The presentation material and the recording of the webcast will be made available at www.oncoinvent.com.

Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.